


Editorial

Welcome to Seminars in Thrombosis and Hemostasis 2025: Toward the Next 50 Years of Publishing and Announcement of New Online Manuscript Submission System

Emmanuel J. Favaloro, PhD, FFSc (RCPA)^{1,2,3} 

¹ Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, Australia

² School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, New South Wales, Australia

³ School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia

Semin Thromb Hemost 2025;51:5–9.

As we head toward 2025, and another year of publishing *Seminars in Thrombosis & Hemostasis* (STH), it is once again my privilege to welcome the reader to the new year. As noted widely in several past editorials, STH was first published in 1974,¹ and so 2024 marked the 50th birthday of STH. Therefore, 2025 will mark the first year that STH enters the next phase, or the second 50 years of publishing. The year 2025 will also mark my 17th year anniversary as Editor in Chief, so I can say with confidence that I am still a relative teenager! Eberhard F. Mammen steered the journal from its inception in 1974 to his passing in 2008, so 34 years. At 17 years, I guess I may have reached the halfway point, although I doubt I will reach the 34-year mark. In any case, a half century of STH publishing represented a landmark worthy of celebration. We started the celebrations in 2022 when we published our first “toward” 50 years celebratory issue.² A second celebratory issue was published in 2023, again marking a “toward” 50 years celebratory issue.³ We published two issues in 2024 to mark the actual 50th year anniversary of STH publishing.^{4,5} All issues were rich with thrombosis and hemostasis themed content of a historical nature, and all issues were well received by our readers. Indeed, several papers from these issues were listed in our most recent most popular download lists.^{6,7}

Changes to the Editorial Board

As is now standard for these “welcome” editorials, I will again sincerely thank all past and current contributors to STH over

the many years, as well as to all past, current, and future Guest Editors who commit their time to advance STH. I also, of course, thank the current and past STH Editorial team. As noted in the last Welcome Editorial,⁸ we bid farewell to several of our senior editors in 2024 (Hau Kwaan, Anne-Mette Hvas, and Ton Lisman). Professor Kwaan retired from all editorial duties; this was after 10 years as a Senior Editor and after 45 years of association with this journal. Professor Kwaan first contributed to STH in 1979,⁹ just a few years after STH began publishing. Professor Hvas was recently appointed dean of the Faculty of Health at Aarhus University,¹⁰ and felt she could no longer commit the time required to continue on as a Senior Editor. Professor Hvas was a Senior Editor of STH from 2021. Ton Lisman was recently appointed as the new (co-)editor in chief of the *Journal of Thrombosis and Haemostasis* (JTH),¹¹ and thus could no longer continue as a Senior Editor of STH. Professor Lisman was Senior Editor of STH from 2015. Both Anne-Mette Hvas and Ton Lisman have stayed on as Associate Editors of the journal, and we wish them the best for their future roles and success in the field. Accordingly, in 2024 we welcomed some new Senior Editors, reflecting their “promotion” from Associate Editors:

- Kristi Smock (United States), who contributed to several Guest Editorial positions in the past, completing two issues around “Laboratory Diagnostics” with Co-Guest Editor Robert Gosselin in 2022 and 2023,^{12,13} and a third issue with Co-Guest Editor Karen Moffat.¹⁴ Kristi is currently compiling a fourth issue on this topic with Co-Guest Editor

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Advances in the Management of Hemophilia and Bleeding Disorders: Achievements and Perspectives; Guest Editors: Antonio Coppola, MD, and Massimo Franchini, MD

© 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc., 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

DOI <https://doi.org/10.1055/s-0044-1791941>.
ISSN 0094-6176.

Karen Moffat, and this issue series has now been established as an ongoing theme for future issue development.

- Julie Brogaard Larsen (Denmark), who has also Co-Guest edited several past issues of STH, beginning from 2017,^{15–18} and is currently compiling an issue on platelets with Joseph Aslan.
- Job Harenberg (Germany), who has been affiliated with STH for decades. He has published nearly 50 papers in STH, a journey he started in 1989,¹⁹ and has Guest Edited eight issues of STH starting from 1994.²⁰
- Maha Othman (Canada), who started her affiliation with STH in 2007,²¹ and has Guest Edited seven issues of STH starting from 2008.²² Maha and I have a shared passion—von Willebrand disease (VWD)—although her main VWD “subtype” of interest is platelet type (PT) VWD, which could be argued is not a subtype of VWD, since the defect lies in the platelet von Willebrand factor (VWF) receptor (glycoprotein Ib [GPIb]), rather than in VWF.²¹

The new Senior Editors join our longer serving Senior Editor, Sam Schulman, who Guest Edits the ongoing composite issue named “Recent Advances in Thrombosis and Hemostasis.” We have now published 10 of these composite issues, which started in 2016,²³ and the 11th issue is near completion.

STH Impact Factor and Publication Metrics

This annual Editorial once also represented the opportunity to reflect on our journal’s Impact Factor (IF) and other journal metrics. However, because of the continuing move to online publication ahead of print publication, a separate detailed editorial was published on these topics in mid-2024.²⁴ In addition to detailing information on the journal’s IF, in part in comparison to trends from other journals publishing in the Thrombosis and Hemostasis space, I also shared many other publication metrics. I will summarize the information on IF as follows:

- The 2023 IF was 3.6, which marked an anticipated decrease over the 2022 IF, which was 5.7.
- The 2022 IF of 5.7 also marked an anticipated decrease over the 2021 IF, which was 6.938.
- The 2021 IF for STH marked a substantive increase over the 2020 IF, which was 4.180, and the 2019 IF, which was 2.892.
- The 2021 IF of 6.398 also represents the highest IF ever achieved by STH, and this was largely due to some highly cited papers related to COVID-19 (coronavirus disease 2019).
- The previous highest IF (4.524) was 10 years ago in 2011.
- In general, most thrombosis and hemostasis focused journals showed an increase in IF from 2020 to 2021, largely on the back of several highly cited COVID-19 related papers, and then a subsequent fall in 2022 due to “waning interest” in COVID-19, and then another fall in 2023, again due to fewer COVID-19 manuscripts and citations.

It should also be noted that the calculations used to generate the yearly IF have evolved over recent years to ensure better representation of online publications, which often precede print versions by several months.²⁴ Indeed, some journals now only publish online. I have included in this editorial an updated summary of the IF trends for journals publishing in the thrombosis/hemostasis space (►Fig. 1). It is also worth mentioning the placement of STH in the journal categories of “Hematology” and “Peripheral Vascular Disease.” STH was ranked 25/97 in the “Hematology” category of the Science Citation Index Expanded (SCIE) in 2023; this position placed STH in Quartile 2 (Q2) of this category, just missing out on being in Q1. This compared with 20/79 in 2022, 21/78 in 2021, 28/76 in 2020, and 36/76 in 2019. Similarly, STH was ranked 22/96 in the “Peripheral Vascular Disease” category of the SCIE in 2023; this position placed STH in Q1 of this category. This compared with 15/67 in 2022, 14/67 in 2021, 21/65 in 2020, and 26/65 in 2019.

I will also share that 2024 marked the highest number of printed pages in all time, publishing well in excess of 1,000 pages (►Fig. 2). This landmark metric was largely due to STH republishing of historical papers, and accompanying commentaries, to help celebrate 50 years of STH publishing. The journal only exceeded 1,000 pages on one other year, 2020, although it also got close to this page count in 2021 and 2022 (►Fig. 2).

STH Content in Progress

As is my practice for the Welcome Editorial, I confirm that STH, as always, will continue to develop plans for the future content of this journal, and we are confident that our journal will be able to continue to bring its readers the high-quality journal that is expected of us. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in ►Table 1. Naturally, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises. Notably, coronavirus disease 2019 (COVID-19) was a primary focus of the journal in the recent past, and we published four issues devoted to this catastrophic disease over recent years.^{25–28} However, STH has now returned to “business as usual,” and so those issues represent the last that STH will publish specifically focused on COVID-19. All future COVID-19 material accepted for publication in STH will simply be placed in our standard “nonthemed” composite issues. Indeed, recent material on COVID-19 seems to be increasingly on the long-term consequences of COVID-19, sometimes called “long COVID” or perhaps better described as “postacute sequelae of COVID-19” (PASC).^{29,30}

STH Production Team and New Online Manuscript Submission System

I also take this opportunity to once again thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal, and in particular, Mansi Agarwal, the current Production Editor for STH, and her production team.




Fig. 1 Impact factor (IF) trends for main journals publishing in the Thrombosis and Hemostasis space, years 2001 to 2023.




Fig. 2 Number of STH printed pages per year from the first issue in 1974 to 2024 inclusive (left y-axis; red symbols) and number of STH issues per year during the same time period (right y-axis; green symbols).

Table 1 Current planned topics for future issues of *Seminars in Thrombosis and Hemostasis*

● Editorial compilations (continuing series focusing on bleeding disorders or laboratory aspects of thrombosis and hemostasis)
● Recent advances in thrombosis and hemostasis (continuing series focusing on thrombotic disorders)
● Laboratory diagnostics for thrombosis and hemostasis (continuing series focusing on laboratory diagnostics)
● Advances in the management of hemophilia and bleeding disorders: achievements and perspectives
● Precision medicine in rare bleeding disorders
● Platelets and hemostatic effectors in personalized medicine
● Hemostasis, thrombosis, and vascular biology in psychiatric disorders
● Tests of global hemostasis in thrombosis and hemostasis

We are also proud to announce that after 50 years of STH publishing, and handling manuscripts originally by mail, and then by e-mail, the publisher has finally established the online manuscript submission system. The online manuscript submission system officially went live on November 1, 2024, and is available at <https://mc.manuscriptcentral.com/sth>. Readers can create log in accounts at the Web site, and manuscripts can now be submitted.

As also noted by the publisher in their separate Publisher announcements:

In November 2024, the journal *Seminars in Thrombosis and Hemostasis* will launch a new service for authors: online manuscript submission via ScholarOne. This system facilitates the process of submitting and reviewing manuscripts in a convenient and transparent way, improving the author and editor experience for *Seminars in Thrombosis and Hemostasis*.

ScholarOne is one of the most prominent systems of its kind and has already proven itself many times over, both in our Thieme journals and internationally.

Through ScholarOne, you can submit your manuscripts anywhere and at any time and access the articles you have already submitted. This significantly reduces e-mail traffic for submission and revision of an article. Furthermore, you will see faster turnaround times, as all steps from submission, review, and possible revision through to publication of your manuscript are bundled together via the online system.

So, please note:

From November 1, 2024, manuscripts for *Seminars in Thrombosis and Hemostasis* will be submitted exclusively via ScholarOne. The author guidelines for *Seminars in Thrombosis and Hemostasis* and further information on submission can be found on the journal's Web site at <https://lp.thieme.de/journals/seminars-in-thrombosis-and-hemostasis/0094-6176>.

In conclusion, I look forward to another interesting year of reading in 2025, being the first of the second 50 years of STH publishing!

Conflict of Interest

None declared.

References

- 1 The first issue of STH. Accessed September 27, 2024 at: <https://www.thieme-connect.com/products/ejournals/issue/10.1055/s-012-55744>
- 2 Favaloro EJ. Celebrating 50 years of *Seminars in Thrombosis and Hemostasis*: part I. *Semin Thromb Hemost* 2022;48(08):871–874
- 3 Favaloro EJ. Celebrating 50 years of *Seminars in Thrombosis and Hemostasis*: part II. *Semin Thromb Hemost* 2023;49(03):212–216
- 4 Favaloro EJ. Celebrating 50 years of *Seminars in Thrombosis and Hemostasis*: part III. *Semin Thromb Hemost* 2024;50(01):4–7
- 5 Favaloro EJ. Celebrating 50 years of *Seminars in Thrombosis and Hemostasis*: part IV. *Semin Thromb Hemost* 2024;50(05):677–681
- 6 Favaloro EJ. 2024 Eberhard F. Mammen Award Announcements: part I—most popular articles. *Semin Thromb Hemost* 2024;50(07):919–932
- 7 Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: part I—most popular articles. *Semin Thromb Hemost* 2023;49(05):417–426
- 8 Favaloro EJ. Welcome to *Seminars in Thrombosis and Hemostasis* 2024: 50 years of publishing. *Semin Thromb Hemost* 2024;50(01):1–3
- 9 Kwaan HC. The pathogenesis of thrombotic thrombocytopenic purpura. *Semin Thromb Hemost* 1979;5(03):184–198
- 10 Professor Anne-Mette Hvas is the new dean of the Faculty of Health at Aarhus University. Accessed September 27, 2024 at: <https://newsroom.au.dk/en/news/show/artikel/professor-anne-mette-hvas-is-the-new-dean-of-the-faculty-of-health-at-aarhus-university/>
- 11 ISTH Announces new Editors for its Flagship Publication, the *Journal of Thrombosis and Haemostasis*. Accessed September 27, 2024 at: <https://www.isth.org/news/633949/ISTH-Announces-new-Editors-for-its-Flagship-Publication-the-Journal-of-Thrombosis-and-Haemostasis.htm>
- 12 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing: part I. *Semin Thromb Hemost* 2022;48(06):631–633
- 13 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing: part II. *Semin Thromb Hemost* 2023;49(06):569–570
- 14 Smock KJ, Moffat KA. Laboratory diagnostics for thrombosis and hemostasis testing-part 3. *Semin Thromb Hemost* 2024;50(08):1047–1048

- 15 Hvas AM, Larsen JB, Pasalic L. Thrombosis and hemostasis in surgery. *Semin Thromb Hemost* 2017;43(07):649–652
- 16 Hvas AM, Larsen JB, Pasalic L. Acquired platelet dysfunction—laboratory and clinical implications. *Semin Thromb Hemost* 2020;46(03):235–237
- 17 Larsen JB, Lisman T, Hvas AM. Preface: altered fibrinolysis—clinical impact and diagnostic challenges. *Semin Thromb Hemost* 2021;47(05):477–479
- 18 Gyldenholm T, Larsen JB. Cancer-associated thrombosis and beyond: biomarkers, treatments, and cancer-hemostasis interactions. *Semin Thromb Hemost* 2024;50(03):325–327
- 19 Harenberg J, Stehle G, Augustin J, Zimmermann R. Comparative human pharmacology of low molecular weight heparins. *Semin Thromb Hemost* 1989;15(04):414–423
- 20 Glycosaminoglycans: I. Guest Editors: J. Harenberg MD & B. Casu Ph.D. Accessed September 27, 2024 at: <https://www.thieme-connect.com/products/ejournals/issue/10.1055/s-002-7584>
- 21 Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. *Semin Thromb Hemost* 2007;33(08):780–786
- 22 Othman M. Molecular genetic testing in hemostasis and thrombosis: the past, the present, and the future. *Semin Thromb Hemost* 2008;34(06):485–489
- 23 Schulman S, Islam MS. Recent advances in thrombosis and hemostasis: part I. *Semin Thromb Hemost* 2016;42(08):805–807
- 24 Favaloro EJ. New Seminars in Thrombosis and Hemostasis 2022 impact factor, most highly cited papers, and other journal metrics. *Semin Thromb Hemost* 2023;49(07):661–669
- 25 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part I. *Semin Thromb Hemost* 2020;46(07):757–762
- 26 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part II. *Semin Thromb Hemost* 2021;47(04):333–337
- 27 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part III. *Semin Thromb Hemost* 2022;48(01):3–7
- 28 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part IV. *Semin Thromb Hemost* 2023;49(01):3–8
- 29 Turner S, Naidoo CA, Usher TJ, et al. Increased levels of inflammatory and endothelial biomarkers in blood of long COVID patients point to thrombotic endothelialitis. *Semin Thromb Hemost* 2024; 50(02):288–294
- 30 Pretorius E, Kell DB. A perspective on how fibrinoid microclots and platelet pathology may be applied in clinical investigations. *Semin Thromb Hemost* 2024;50(04):537–551